Sub-study of the Essen Study Centre for the ENTAiER Trial

Elderly Patients Clinical Trial

Official title:

Sub-study of the Essen Study Centre With Proteome and Telomer Analyses and Qualitative Parameters for the ENTAiER Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04532073
• Other study ID #: 20-9421-BO
• Status: Completed
• Phase: N/A
• Start date: July 27, 2021
• Est. completion date: December 7, 2022

Study information

• Verified date: December 2023
• Source: Universität Duisburg-Essen
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The present study is a sub-study of the ENTAiER study. The ENTAiER study is a multicenter, randomized, controlled study to evaluate the efficacy and safety of eurythmy therapy and Tai Chi in comparison to standard care in chronically ill older patients with an increased risk of falling.

In addition to the main questions of the ENTAiER study, three additional questions are being investigated at the Hospital Essen-Steele: Proteome and telomere analyses as well as qualitative parameters are recorded and examined. The aim is to compare the changes in proteomes, telomeres and qualitative factors under eurythmy therapy, Tai Chi and standard care in chronically ill older patients with an increased risk of falling.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 60
• Est. completion date: December 7, 2022
• Est. primary completion date: December 7, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 65 Years and older

Eligibility

Inclusion Criteria:

• At least 65 years.

• Chronic disease (musculoskeletal, neurological, internal medicine).

• Increased risk of falling (Berg Balance Scale Score 49 or less).

• Medical history: feeling of balance disturbance in the past.

• Independent living at home or in an old people's or retirement home.

• Regular participation in a one-hour event is possible.

• Sufficiently mobile to leave the place of residence independently at least twice a week

• Written declaration of consent.

Exclusion Criteria:

• Disease that restricts participation (e.g. terminal disease, heart failure NYHA III-IV, unstable angina pectoris, uncontrolled seizure disorder, decompensated lung disease that already leads to shortness of breath during light activity, advanced cancer, chemo- or radiotherapy ongoing or during the last 3 months, amputation of one or both legs)

• Complete dependence on the rollator.

• Visual, hearing or speech problems that limit the understanding of the study documents and processes.

• Major cognitive impairment (MoCA score 18 or less).

• High risk of needing individual supervision during group sessions.

• Severe personality disorder or psychiatric illness, alcoholism or other substance dependence affecting the group sessions.

• Life expectancy under 1 year.

• Permanent bed-riddenness expected in less than one year.

• Regular participation in Tai Chi or EYT in the last 6 months.

• Participation in intensive sports activities in the last month (e.g. training in the fitness centre or in sports groups which lead to breathlessness and sweating; skiing, mountaineering in high mountains).

• Patients who cannot understand the nature, meaning and necessities of participating in a study.

• Participation in another clinical trial within 3 months prior to screening for the ENTAiER trial or concurrent participation in another trial that may interfere with this trial.

Related Conditions & MeSH terms

• Chronic Disease
• Chronically Ill
• Elderly Patients
• Increased Risk of Falling

Intervention

Other:
• Eurythmy Therapy
A mindfulness-oriented movement therapy
• Tai Chi
A martial art developed in China, which in recent times is often regarded as a system of movement theory or gymnastics
• Standard Care
Treatment process that a clinician should follow for a certain type of patient

Locations

Country	Name	City	State
Germany	Kliniken Essen-Mitte	Essen

Sponsors (3)

Lead Sponsor	Collaborator
Universität Duisburg-Essen	Software AG Stiftung, Universität Freiburg

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in proteomic analysis from baseline to after intervention	A maximum of 500 µL plasma is used for the proteomic studies. The proteins are digested tryptically, a concentration determination is performed by amino acid analysis and the peptide samples are then measured by different mass spectrometric methods (data dependent (DDA) and independent detection (DIA), proteome-wide prediction of peptide tandem mass spectra by deep learning (Prosit), etc.). The results obtained are then verified by Western blot, ELISA and/or a targeted mass spectrometric method (parallel reaction monitoring)	Before intervention (week 0) and after intervention (6 months)
Primary	Change in telomer analysis from baseline to after intervention	The telomere length is determined from blood samples using quantitative real-time PCR (TaqMan) from genomic DNA.	Before intervention (week 0) and after intervention (6 months)
Primary	Qualitative parameter	By means of semi-structured interviews of maximum 60 minutes per participant, the effects of the intervention are to be recorded qualitatively.	After intervention (6 months)